PCN188 - ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN

Shunya Ikeda; Masatoshi Kudo; Namiki Izumi; Satoshi Kaneko; Masahiro Kobayashi; Mie Azuma; Ronda Copher; Suchin Virabhak; David Mitchell; Genevieve Meier; Mika Ishii

doi:10.1016/j.jval.2018.09.270

Related publications

Article2019

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Masahiro Kobayashi, Masatoshi Kudo, Namiki Izumi, Shuichi Kaneko, Mie Azuma, Ronda Copher, Genevieve Meier, Janice Pan, Mika Ishii, Shunya Ikeda

Article2023

198P Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan

Namiki Izumi, Masatoshi Kudo, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yutaka Kondo, Kazuhisa Yabushita, K Motoyoshi, Junji Furuse

Article2021

A multicenter observational study of lenvatinib for unresectable hepatocellular carcinoma in Japan.

Namiki Izumi, Masatoshi Kudo, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, Katsuaki Motoyoshi, Junji Furuse

Article2017

Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan

Akihiro Nishie, Satoshi Goshima, Hiroki Haradome, Etsuro Hatano, Yasuharu Imai, Masatoshi Kudo, Masanori Matsuda, Utaroh Motosugi, Satoshi Saitoh, Kengo Yoshimitsu, Bruce Crawford, Eliza Kruger, Graeme Ball, Hiroshi Honda

Article2023

Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients

Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Sara Lonardi, Fabio Piscaglia, Hong Jae Chon, Gianluca Masi, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini